A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

Elena Garralda(Memorial Sloan Kettering Cancer Center), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), J. Palcza(Merck & Co., Inc., Rahway, NJ, USA (United States)), S. Jha(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yiyun Lou(Zhejiang Chinese Medical University), Martin Wermke(National Center for Tumor Diseases), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ravit Geva(Tel Aviv Sourasky Medical Center), Akash Patnaik(Johannes Gutenberg University Mainz), Seock‐Ah Im(Seoul National University), Anson K. Abraham(Merck & Co., Inc., Rahway, NJ, USA (United States)), Talia Golan(Sheba Medical Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Jasmine Healy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
ESMO Open
December 1, 2022
10.1016/j.esmoop.2022.100639
Cited by 87

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k